ArticleMelanoma management2019
Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).
Article in Melanoma management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinical Pharmacology Characterization of the First-In-Class Oncolytic Viral Therapy T-VEC in Adults and Pediatric Subjects.Journal of clinical pharmacology · 2026Trial
- Tuning epigenetics to enhance cancer virotherapy.Acta pharmaceutica Sinica. B · 2026Review
- Oncolytic viruses and cytokine-based gene therapies reprogram the tumor microenvironment.Nature cancer · 2026Review
- Review
- Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis.Annals of surgical oncology · 2025Article
- Review
- Therapy with oncolytic viruses: progress and challenges.Nature reviews. Clinical oncology · 2023Review
- Durable melanoma control following disseminated talimogene laherparepvec herpetic infection.JAAD case reports · 2022Article
- Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class.Frontiers in molecular biosciences · 2022Review
- Surgical Resection After Talimogene Laherparepvec for Melanoma: Persistent Fuorodeoxyglucose Avidity on Positron Emission Tomography Despite No Viable Disease.The American surgeon · 2021Article
- Advances in Targeting Cutaneous Melanoma.Cancers · 2021Review
- Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.Journal for immunotherapy of cancer · 2021Article
- Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2).Melanoma management · 2020Article
- Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma.Cancers · 2020Review
- Welcome to volume 7 ofMelanoma management · 2020Article
- Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients.Cancer immunology, immunotherapy : CII · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimTalimogene laherparepvec (T-VEC) is an intralesional treatment for unresectable cutaneous, subcutaneous and nodal melanoma. COSMUS-1 was conducted to examine how T-VEC is used in US clinical practice. MATERIALS &
methodsA chart review was conducted at seven centers, with 78 patients screened and 76 eligible.
resultsPatients began treatment with T-VEC between October 2015 and December 2016. Median follow-up was 9.4 months. Twenty percent of patients (n = 15) completed T-VEC treatment with no remaining injectable lesions or pathologic complete response. Flu-like symptoms were the most commonly reported adverse events (n = 8; 10.5%), followed by lesion ulceration (n = 4; 5.3%). No herpetic lesions or infections were reported.
conclusionT-VEC was well tolerated and showed clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.